Model‐based approach to identify predictors of paclitaxel‐induced myelosuppression in “real‐world” administration
Abstract Taxanes are currently the most frequently used chemotherapeutic agents in cancer care, where real‐world use has focused on minimizing adverse events and standardizing the delivery. Myelosuppression is a well‐characterized, adverse pharmacodynamic effect of taxanes. Electronic health records...
Main Authors: | Ahmed M. Salem, Erik Dvergsten, Sanja Karovic, Michael L. Maitland, Mathangi Gopalakrishnan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-07-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.12963 |
Similar Items
-
Myelosuppression Rates with Administration of Nafcillin with and without Rifampin in Pediatric Patients
by: Jolly Kuriakose, et al.
Published: (2022-06-01) -
Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience
by: Shinya Tsuboi, et al.
Published: (2023-01-01) -
Correction to: Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience
by: Shinya Tsuboi, et al.
Published: (2023-04-01) -
Predictors of Myelosuppression for Patients with Head and Neck Squamous Cell Carcinoma After Induction Chemotherapy
by: Wen-qing Chen, et al.
Published: (2024-01-01) -
Lurasidone Induced Thrombocytopenia: Is it a Signal of Drug Induced Myelosuppression?
by: Mohammad Rafi, et al.
Published: (2018-03-01)